Heart failure & cardiomyopathies
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial
Authors' conclusion
Immediate addition of empagliflozin to standard therapy improves echocardiographic parameters of LAV in patients following recompensation of ADHF.
Study context
- Population
- Patients with acute decompensated heart failure (ADHF), randomized within 12 h following hospital admission, irrespective of left ventricular ejection fraction or diabetespatients enrolled and randomized
- Participants
- 60 patients
- Exposure
- Empagliflozin or placebo in addition to standard medical treatment over 5 days
- Outcome
- Change in left atrial volume (LAV) ∆tB-tC
- Follow-up
- After 5 days of treatment
Methodological detailspre-defined secondary analysis
- Pre-defined secondary analysis
Main finding
As reported in the abstract
| Group | Value | 95% CI |
|---|---|---|
| Empagliflozin | ∆tB-tC 30.9 ± 27.4 | 20.1-41.7 |
| Placebo | ∆tB-tC 10.5 ± 26 | 0.4-20.5 |
Value
Empagliflozin∆tB-tC 30.9 ± 27.4
Placebo∆tB-tC 10.5 ± 26
95% CI
Empagliflozin20.1-41.7
Placebo0.4-20.5
- Empagliflozin vs placebo: P = <0.001 — relevant decrease in LAV with empagliflozin
Observational data: associations, not effects.
Further findings
| Outcome | Empagliflozin | Placebo | P value |
|---|---|---|---|
| Change in left atrial end-systolic volume index (LAESVI) ∆tB-tC · After 5 days of treatmentDecrease in LAESVI with empagliflozin | ∆tB-tC 15.7 ± 15.1 | ∆tB-tC 9.7 ± 10.2 | P = 0.016 |
| 95% CI | 9.8-21.6 | 5.7-13.6 |
Original publication
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial. Eur Heart J Cardiovasc Pharmacother. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →